Palo Alto pain management startup Carbylan vies for $86M IPO

Carbylan CEO David Renzi

Biotech startup Carbylan Therapeutics is looking to raise $86 million in an IPO to support its injectable osteoarthritis pain treatment, which is currently in Phase III with another late-stage trial on the way in mid-2015.

According to the company's SEC filing Monday, its Hydros-TA candidate is an intra-articular injectable painkiller that combines short-term and long-term relief for osteoarthritis of the knee using the company's own cross-linked technology. Current treatments, the company said, include corticosteroids for short-term relief and viscosupplements for longer-term pain management, but Carbylan's cross-linked delivery method allows for a one-injection treatment that includes both the corticosteroid triamcinolone acetonide and a hyaluronic acid viscosupplement. In Phase II the injection showed better pain reduction at all points than Sanofi's ($SNY) market-leading viscosupplement Synvisc-One.

As reported in the Silicon Valley Business Journal, Carbylan has raised funding of $31 million since 2005, the biggest stakeholders being InterWest Partners, Alta Capital Partners and Vivo Ventures. The company has accumulated a deficit of $43 million since the end of September, $8 million of which occurred in the first 9 months of 2014.

Currently, Carbylan has no other products for sale and is devoted entirely to Hydros, for which it's expecting the ongoing Phase III results in mid-2015 and the second trial's outcome at the end of the year. According to the filing, though, the candidate is "potentially best-in-class."

The company would be listed on the Nasdaq under the symbol "CBYL."

- here's the SEC filing
- and here's the Silicon Valley Business Journal report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.